Max Marchione

Couple of weeks ago had the pleasure of sharing my story to Alexander Benkendorf about starting CastPrint and later moving on to join Verge HealthTech Fund and the learning along the way. Some topics we discussed: 💡What does it take to bring innvation in healthcare 💡How did my startup background help me better prepare for VC work 💡How founders can better engage with VCs and what are the tips and tricks from the "other side" Thanks Alexander for having me!

15

1 Comment

Someone broke down the estimated costs of a $15 Sweetgreen salad. We need these cost graphics for digital health to help future founders. Especially for tech enabled cos, the greatest cost is labor. Much of the "value created" is in curation and matching, which means the gross margins are reliant on labor arbitrage. Pay someone $X, but get paid $X Y% per visit. The challenge with healthcare is that you often have to pick one of two business models: 1. specialized, low volume, high cost, low gross margin % 2. generalized, high volume, low cost, high gross margin % I'd argue founders should focus on gross dollars over the lifetime of the customer (like Jeff Bezos said) instead of gross margin %'s, but we'll leave that for another time. The challenge is that many tech enabled digital health cos have high cost of goods sold (labor) and moderately high product, design, and engineering budgets. We must build differentiated solutions for patients, clinicians, and clients to be out incumbents, however, we're realizing that companies are ultimately valued on the discounted value of future cash flows. And the high SG&A costs at most organizations might be inbalanced to the unit economics of the business. I'm not sure the math pencils out for everyone unfortunately. But I'm just a guy on the internet, would love to hear the thoughts from those smarter than I (you!). Comment below. --- p.s. I have no idea the accuracy of the graphic and not an investor in Sweetgreen. Cheers. Credit: David Crowther

113

27 Comments

The GLP-1 space has continued to explode, with the potential for impact expanding to cardiovascular risk, sleep apnea, and liver disease. So who are the emerging players poised to challenge Lilly and Novo? The incoming players to watch are a mix of startups and incumbents. In the startup realm, Viking Therapeutics, Inc., and Altimmune, Inc. have gained significant attention as their GLP-1 candidates demonstrate solid weight-loss outcomes. For San Diego based Viking, weekly doses of VK2735 delivered weight loss of up to 13% compared to placebo in a Phase 2 trial. Perhaps most exciting, the weight loss did not plateau at any time during the 13 week study, suggesting longer duration doses would result in further weight loss. Meanwhile, Altimmune's Pemvidutide (being studied for both obesity and MASH) is on track for an end of phase 2 FDA meeting in Q3 of this year. Notably, Pemvidutide has showed promise in limiting the amount of weight loss derived from muscle, which is a notable problem with the existing GLP-1s. A recent phase 2 trial showed only ~25% of weight loss was from lean mass, more in line with the ratio seen in typical diet & exercise programs. There are also several incumbents working hard to establish their presence. Roche's $2.7B acquisition of California-based Carmot Therapeutics, Inc. Therapeutics in December and Amgen's MariTide are both notable. Roche recently announced data from a Phase 1B study for CT-388 showing placebo-adjusted weight loss of ~19%, with 85% of participants seeing weight loss of more than 10%. Not to be left out, Amgen has recently advanced MariTide into Phase 2 studies, with Phase 1 results published in February showing weight loss of up to 15% in 12 weeks, with some dosage levels only required once a month. To have a credible chance at challenging the existing market leaders, new GLP-1s will have to demonstrate meaningful improvements on the following: 1. Dosage - most approved therapies today (with the exception of Rybelsus) are subcutaneous injections, given weekly. Having an easier form (tablet) or frequency (bi-weekly or even monthly) would be a big advantage. 2. Preservation of lean muscle mass - helping patients derive weight gain from regular adipose tissue instead of muscle mass. 3. Benefits beyond weight loss. Novo's recent FDA label expansion for Wegovy for reducing the risk of serious cardiovascular events provides a blueprint of how to expand the area these medicines can be helpful in. While there are many companies active in the space, it's worth noting just how large a lead Lilly and Novo have in this future $100B market. A recent GlobalData report noted that even by 2029, these two giants will have ~80% of the market between them. That said, 20% of a $100B market is still a sizable prize for other innovators, and continued innovation will only help patients.

412

19 Comments

🔥Tune In to the Latest Fireside Chat with a VC in Healthech🔥 What percentage of VCs are former founders? 30% maybe more? I'd think a fair amount, yet how *exactly* does that transition happen and what perspectives change *radically* afterwards? Sigvards Krongorns shared exactly that - his journey from PwC consultant to Healtech founder, to a VC shaping the future of Healthtech startups. What we talked about: ✨ Sigvards' transition from a PwC consultant to founder to a VC ✨ What steps are necessary to bring innovative medical devices from concept to market ✨ How being a founder can prepare you for a role in venture capital ✨ What strategies help navigate the regulatory landscape in healthtech startups ✨ The right way to engage with VCs for startup funding ✨ What future trends in venture capital and Healthtech look like #HealthTech #VentureCapital #Innovation #StartupJourney #HealthcareInnovation #Entrepreneurship #FiresideChat #VentureCapitalInsights Full conversation can be found here:

32

5 Comments

A new era of deep tech has emerged. First time funds will raise “unheard of” amounts of capital to fuel next gen deep tech startups - producing outsized, superior returns for LP’s compared to the rest. Prudent investors will act on this data and shift investment strategy as LP’s or risk being left behind savvy wealth managers and CIO’s / FO’s who saw this trend begin 4 years ago.

100

8 Comments

Looking beyond #VC funding for your #startup? Aakash Shah of Wyndly (YC W21) reveals how he built a multi-million dollar #healthtech company using creative capital strategies. Learn how he leveraged Y Combinator's network and alternative funding methods to revolutionize allergy treatment. In case you missed it, you can watch the #FundraisingDemystified #podcast here: https://lnkd.in/eZT63YS4

5

2 Comments

A recent monumental milestone for the femtech industry: Flo Health secured $200M in funding, achieving a valuation of over $1 billion as the world's first femtech unicorn. It’s important to acknowledge both the progress and the paradoxes within this achievement. Flo Health, a platform empowering women with vital health insights, was founded by two male cofounders. 🤔 This brings to light a critical discussion about representation and inclusivity in the femtech space. While their contribution is commendable, it underscores the necessity for more female founders and leaders in industries that primarily serve women. As the founder of BAD BITCH EMPIRE dedicated to breaking down barriers for women in business and investing, I see this as a call to action. We need more women at the helm of innovative solutions addressing our unique health needs. It's not just about creating products for women; it's about ensuring these products are driven by the voices and experiences of women themselves. This historic funding round proves that femtech is not only vital but also a lucrative market. Now, let's channel this momentum to elevate more female entrepreneurs, investors, and leaders who can drive the next wave of femtech innovations. #Femtech #WomenInTech #FemaleFounders #InvestInWomen https://lnkd.in/euwbhqVB

50

4 Comments

In 2023, only 13.2% of all startup founders were women. Startups with all-women founders raised less than 2% of all venture capital funding. Only 15% of unicorns that went public in 2021 had at least one female founder. April Koh is one of the rare founders who has made it through the gauntlet to get to this point. While companies are struggling to raise more capital in this environment because the hurdles are higher, imagine how much harder it is for a woman founder. It is a triumph and credit to how she has built Spring Health into a $3.3 billion valuation. We are all pulling for you April, because the more Spring Health's there are in the world, the more likely we are to see women unicorn founders in the future.

114

4 Comments

“Pipe dreams” become a reality if you understand the value of your proposition and when people investing in you also realize the growth of an industry. Ideas are great, execution is better. Execute your idea and you’ll reach a level that pipe dreams become a “pipe reality”.

3